MicroPort Scientific Corp.
0.68
EUR
-0.01
(-2.16%)
ISIN
KYG608371046
CUSIP
G60837104
Return %
Stock
S&P 500
1Y
-48.48
14.20
3Y
-58.28
81.12
5Y
-86.86
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Semi-annual Revenue
USD
•
in mil. unless spec.Semi-annual Earnings Per Share
USD
•
in mil. unless spec.Semi-annual Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Jonathan W. Chen
- Full Time Employees
- 6,547
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 1601 Zhangdong Road Shanghai SH China 201203
- IPO Date
- Sep 24, 2010
- Website
- microport.com
- Similar Companies
- Business
- MicroPort Scientific Corporation (0853.HK) is a global medical technology company that researches, develops, manufactures, and markets innovative medical devices across multiple segments, including cardiovascular, orthopedics, endovascular and peripheral vascular, neurovascular, heart valve, cardiac rhythm management, surgical robotics, and surgical devices. The company offers a broad portfolio of products such as drug-eluting stents including Firesorb fully bioresorbable stent, coronary stents, PTCA balloon dilatation catheters, implantable cardiac rhythm management devices like pacemakers and defibrillators, reconstructive joints, spine and trauma orthopedic implants, transcatheter aortic valve replacement systems like VitaFlow Liberty Flex, Toumai multi-port laparoscopic surgical robots with fluorescence imaging, flow-diverting stents, branched aortic stent-graft systems like Cratos, and pulsed field ablation catheters like PulseMagic TrueForce; these solutions target coronary artery diseases, structural heart conditions, orthopedic reconstructions, neurovascular interventions, and minimally invasive surgeries, serving hospitals and healthcare providers worldwide. Founded in 1998 and headquartered at 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Shanghai, China, MicroPort operates through subsidiaries such as MicroPort CardioFlow (2160.HK), MicroPort NeuroScientific (2172.HK), MicroPort MedBot (2252.HK), MicroPort EP (688351.SH), MicroPort Endovastec (688016.SH), MicroPort CRM, MicroPort Orthopedics, and MicroPort Surgical, with R&D and manufacturing facilities in China, the United States, France, Italy, Germany, the UK, and the Dominican Republic, and products available in over 100 countries across more than 20,000 healthcare institutions. In recent developments, MicroPort CRM, a key subsidiary, announced a proposed US$680 million strategic merger with MicroPort CardioFlow in October 2025 to create a diversified cardiology platform enhancing heart disease solutions including transcatheter and surgical options for structural heart diseases and cardiac rhythm disorders; this transaction, one of the largest under Hong Kong Listing Rules Chapter 18A, remains subject to closing conditions. The company welcomed SIIC Capital as a new strategic shareholder through a proposed restructuring to leverage state-owned resources for core business growth, higher governance standards, and capacity upgrades, as highlighted in its 2025 interim results showing 235.3% year-over-year revenue growth in certain segments. At the 91st China International Medical Equipment Fair in April 2025, MicroPort unveiled over 80 innovations across eight body systems, including the MT-4000 Toumai surgical robot, Firesorb bioresorbable stent, and VitaFlow Liberty Flex TAVI system, alongside 2024 regulatory approvals like NMPA for Cratos Branched Aortic Stent-graft and Tipspear Transjugular Liver Access Set, plus greenlight for Hector triple-branch stent; these advancements build on 307 first-time approvals in 44 countries.